Core C Microbiology and Virology. For the past 31 years, the Microbiology and Virology Core has supported the projects of this Program by creating and maintaining an extensive Infectious Diseases (ID) database. This database has been critical for projects that have Infectious Disease endpoints. Over the years the function and services provided by the Core have expanded, mainly driven by the availability of highly sensitive and quantitative diagnostic capabilities, which made it imperative to have standardized definitions and interpretations of diagnostic test results for the Programs. Therefore, all infection endpoints for clinical trials or studies related to the aims of the projects are discussed with the Core director, the Core provides statistical support and data management for specific ID analyses related to the projects. State-of - the-art diagnostic capabilities are provided and continuous efforts are made to improve diagnostic capabilities for pathogens relevant to hematopoietic cell transplant recipients. The Core also maintains a prospective sample collection to facilitate infection diagnosis using research diagnostic assays. In addition, the Core provides monitoring capabilities for immune reconstitution studies. Specifically, the Core provides the following services: 1. State-of-the-art diagnostic molecular capabilities for the detection of occult infections and pathogen quantitation. These assays will be applied in patients with idiopathic pneumonia syndrome and for optimizing BAL and tissue-based quantitative molecular diagnosis. 2. Provision of data management and statistical services to Project and Core leaders. 3. Data entry and quality control of the IDdatabases. 4. Assistance to Project and Core leaders in defining ID endpoints, including assurance of appropriate use of ID database, and assistance in analysis of ID data. 5. Maintaining a tissue sample repository (BAL and blood). 6. Antigen preparation for T cell assays.
to Public Health: This Core will assist Projects by applying new diagnostic tests for infectious agents to samples from patients undergoing allogeneic hematopoietic cell transplantation and by making accurate and consistent diagnoses of infectious complications. The Core will store clinical samples, apply a battery of research diagnostic tests, establish infectious disease diagnoses, and correlate infections with transplant outcomes. These efforts will not only aid this Program Project in achieving its goals, but will likely lead to a better understanding of infectious complications in other immunosuppressed patient populations.
|Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313|
|Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764|
|Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531|
|Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580|
|Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541|
|McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807|
|Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193|
|Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515|
|Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334|
|Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849|
Showing the most recent 10 out of 1845 publications